Neurgian Technologies

Neurgian Technologies is a preclinical-stage biotechnology company focused on developing small molecule therapeutics for neurodegenerative diseases. The company's core technology targets the pathological aggregation of TAR DNA-binding protein 43 (TDP-43), which is a hallmark of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). Founded on research from the University of Pennsylvania, Neurgian aims to discover compounds that can prevent or dissolve these toxic protein clumps to preserve neuronal function. Their approach represents a potential disease-modifying strategy for conditions with significant unmet medical needs. The company leverages a proprietary screening platform to identify molecules that modulate protein folding and aggregation.